GlassScriptPhysician profile
Amber Dreiling
NPI 1962018234
$485.52
in general payments reported to CMS, 2019-2025
11 companies · $486 in 2025
The $486 reported for 2025 was more than what 76% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $485.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $100.87 | 2025 | |
| Kerecis Limited | $98.37 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Smith+Nephew, INC. | $89.02 | 2025 | Collagenase Santyl |
| Mimedx Group, INC. | $45.73 | 2025 | |
| Organogenesis INC. | $33.06 | 2025 | Puraply Wound Matrix, Affinity |
| Djo, LLC | $28.14 | 2025 | Donjoy |
| Hydrofera LLC | $19.49 | 2025 | Hydrofera Blue |
| Solventum Corporation | $19.33 | 2025 | Activ.A.C. |
| Viatris Specialty LLC | $19.29 | 2025 | Yupelri |
| Reprise Biomedical, INC. | $16.97 | 2025 | Miro3d |
| Melinta Therapeutics, LLC | $15.25 | 2025 | Orbactiv, Kimyrsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Dreiling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.